MIF promotes cell invasion by the LRP1-uPAR interaction in pancreatic cancer cells

MIF promotes cell invasion by the LRP1-uPAR interaction in pancreatic cancer cells

IntroductionPancreatic ductal adenocarcinoma (PDAC) is characterized by high aggressiveness and a hypoxic tumour microenvironment. Macrophage migration inhibitory factor (MIF) is a hypoxia-related pleiotropic cytokine that plays important roles in cancer. However, its role in PDAC progression has no...

Full description

Bibliographic Details
Main Authors:	Huizhi Sun, Runfen Cheng, Danfang Zhang, Yuhong Guo, Fan Li, Yanlei Li, Yue Li, Xiaoyu Bai, Jing Mo, Chongbiao Huang
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-01-01
Series:	Frontiers in Oncology
Subjects:	MIF uPAR LRP1 hypoxia spatial transcriptomics
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2022.1028070/full

Similar Items

Identification of uPAR Variants Acting as ceRNAs in Leukaemia Cells
by: Mariaevelina Alfieri, et al.
Published: (2022-04-01)

The uPA/uPAR System Orchestrates the Inflammatory Response, Vascular Homeostasis, and Immune System in Fibrosis Progression
by: Yosuke Kanno
Published: (2023-01-01)

Redrawing Urokinase Receptor (uPAR) Signaling with Cancer Driver Genes for Exploring Possible Anti-Cancer Targets and Drugs
by: Yu-Ching Chang, et al.
Published: (2023-10-01)

New Pieces in the Puzzle of uPAR Role in Cell Migration Mechanisms
by: Anna Gorrasi, et al.
Published: (2020-11-01)

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin
by: Oh F, et al.
Published: (2018-09-01)

Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease
by: Yang Cheng, et al.
Published: (2022-01-01)

Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor
by: Gujrati Meena, et al.
Published: (2011-10-01)

Integrin-uPAR signaling leads to FRA-1 phosphorylation and enhanced breast cancer invasion
by: Matthew G. Annis, et al.
Published: (2018-01-01)

Role of flow cytometry in multiple myeloma and the prognostic significance of CD87 (uPAR) expression
by: Murat Albayrak, et al.
Published: (2010-09-01)

Targeting uPAR by CRISPR/Cas9 System Attenuates Cancer Malignancy and Multidrug Resistance
by: Kun Wang, et al.
Published: (2019-02-01)

The Association of uPA, uPAR, and suPAR System with Inflammation and Joint Damage in Rheumatoid Arthritis: suPAR as a Biomarker in the Light of a Personalized Medicine Perspective
by: Maurizio Benucci, et al.
Published: (2022-12-01)

Urokinase-Type Plasminogen Activator Receptor (uPAR) Cooperates with Mutated <i>KRAS</i> in Regulating Cellular Plasticity and Gemcitabine Response in Pancreatic Adenocarcinomas
by: Luogen Peng, et al.
Published: (2023-03-01)

Urokinase Receptor uPAR Downregulation in Neuroblastoma Leads to Dormancy, Chemoresistance and Metastasis
by: Anna A. Shmakova, et al.
Published: (2022-02-01)

suPAR, a Circulating Kidney Disease Factor
by: Changli Wei, et al.
Published: (2021-10-01)

Targeting the Urokinase-Type Plasminogen Activator Receptor (uPAR) in Human Diseases With a View to Non-invasive Imaging and Therapeutic Intervention
by: Julie Maja Leth, et al.
Published: (2021-08-01)

The Urokinase Receptor (uPAR) as a “Trojan Horse” in Targeted Cancer Therapy: Challenges and Opportunities
by: Virginia Metrangolo, et al.
Published: (2021-10-01)

Human antibody VH domains targeting uPAR as candidate therapeutics for cancers
by: Xiaojie Chu, et al.
Published: (2023-10-01)

The Urokinase Receptor: A Multifunctional Receptor in Cancer Cell Biology. Therapeutic Implications
by: Anna Li Santi, et al.
Published: (2021-04-01)

The Perspective of Vitamin D on suPAR-Related AKI in COVID-19
by: Tzu-Hsien Liao, et al.
Published: (2022-09-01)

Urokinase-type plasminogen activator receptor (uPAR), tissue factor (TF) and epidermal growth factor receptor (EGFR): tumor expression patterns and prognostic value in oral cancer
by: Anders Christensen, et al.
Published: (2017-08-01)

Mapping the topographic epitope landscape on the urokinase plasminogen activator receptor (uPAR) by surface plasmon resonance and X-ray crystallography
by: Baoyu Zhao, et al.
Published: (2015-12-01)

Orientational Preferences of GPI-Anchored Ly6/uPAR Proteins
by: Maxim M. Zaigraev, et al.
Published: (2022-12-01)

<i>Helicobacter pylori</i> Colonization Drives Urokinase Receptor (uPAR) Expression in Murine Gastric Epithelium During Early Pathogenesis
by: Warner Alpízar-Alpízar, et al.
Published: (2020-07-01)

Growth Inhibition of MDA-MB-231 Cell Line by Peptides Designed based on uPA
by: Parastoo Tarighi, et al.
Published: (2015-10-01)

CEA, EpCAM, αvβ6 and uPAR Expression in Rectal Cancer Patients with a Pathological Complete Response after Neoadjuvant Therapy
by: Daan Linders, et al.
Published: (2021-03-01)

ALG3 Promotes Peritoneal Metastasis of Ovarian Cancer through Increasing Interaction of α1,3-mannosylated uPAR and ADAM8
by: Xinyuan Cui, et al.
Published: (2022-10-01)

The uPAR System as a Potential Therapeutic Target in the Diseased Eye
by: Maurizio Cammalleri, et al.
Published: (2019-08-01)

uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study
by: Marie Øbro Fosbøl, et al.
Published: (2021-06-01)

Aβ1-42 Accumulation Accompanies Changed Expression of Ly6/uPAR Proteins, Dysregulation of the Cholinergic System, and Degeneration of Astrocytes in the Cerebellum of Mouse Model of Early Alzheimer Disease
by: Maxim L. Bychkov, et al.
Published: (2023-10-01)

Identification of a Novel Small RNA Encoded in the Mouse Urokinase Receptor uPAR Gene (Plaur) and Its Molecular Target Mef2d
by: Karina D. Rysenkova, et al.
Published: (2022-07-01)

uPAR (PLAUR) Marks Two Intra-Tumoral Subtypes of Glioblastoma: Insights from Single-Cell RNA Sequencing
by: Yue He, et al.
Published: (2024-02-01)

Enterococcus faecalis promotes a migratory and invasive phenotype in colon cancer cells
by: Ashley J. Williamson, et al.
Published: (2022-05-01)

Bispecific Targeting of EGFR and Urokinase Receptor (uPAR) Using Ligand-Targeted Toxins in Solid Tumors
by: Felix Oh, et al.
Published: (2020-06-01)

The Role of the Plasminogen Activation System in Angioedema: Novel Insights on the Pathogenesis
by: Filomena Napolitano, et al.
Published: (2021-02-01)

(-)-Epigallocatechin-3-Gallate Prevents IL-1β-Induced uPAR Expression and Invasiveness via the Suppression of NF-κB and AP-1 in Human Bladder Cancer Cells
by: Dhiraj Kumar Sah, et al.
Published: (2022-11-01)

Fibrinolytic System and Cancer: Diagnostic and Therapeutic Applications
by: Niaz Mahmood, et al.
Published: (2021-04-01)

Cleavage of the urokinase receptor (uPAR) on oral cancer cells: regulation by transforming growth factor – β1 (TGF-β1) and potential effects on migration and invasion
by: Synnove Norvoll Magnussen, et al.
Published: (2017-05-01)

ICAM-1-suPAR-CD11b Axis Is a Novel Therapeutic Target for Metastatic Triple-Negative Breast Cancer
by: Dong Li, et al.
Published: (2023-05-01)

Exogenous Urokinase Inhibits Proteasomal Degradation of Its Cognate Urokinase Plasminogen Activator Receptor
by: Ran Zhu, et al.
Published: (2022-08-01)

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer
by: Bing-Tao Zhai, et al.
Published: (2022-03-01)